Our primary objective was to estimate the percentage of seniors with rheumatoid arthritis (RA) receiving disease-modifying agents (DMARDs) within the first year of diagnosis.
The authors assembled an incident RA cohort from Ontario physician billing data for 1997-2006. They used a standard algorithm to identify 24,942 seniors with RA, based on >2 billing codes, >60 days apart but within five years. Drug exposures were obtained from pharmacy claims data. They followed subjects for one year, assessing if they had been exposed (defined as ≥1 prescription) to one or more DMARD within the first year of RA diagnosis. The authors assessed secular trends and differences for subjects who had received rheumatology care (defined as ≥1 rheumatology encounter) versus those who had not.
In total, just 39% of the 24,942 seniors with new-onset RA identified over 1997-2006 were exposed to DMARD therapy within one year of diagnosis. This increased from 30% in 1997, to 53% in 2006. Patients whose care involved a rheumatologist were more likely to be exposed to DMARDs than those who had no rheumatology care. In 2006, 67% of subjects receiving rheumatology care were exposed to DMARDs, versus 21% of those with no rheumatology care.
Improvements in RA care have occurred but more efforts are needed. Subjects receiving rheumatology care are much more likely to receive DMARDs, as compared to those with no rheumatology care. This emphasizes the key role of rheumatologists.